Completed PHASE3 INTERVENTIONAL NCT00872560

Comparison of 2 NovoFine® Needles on the Reflux of Insulin

Insulin Leakage and Pain Perception in IDDM Children or Adolescents, Where the Injections Are Performed With NovoFine™ 6 x 0.30 mm Needles and NovoFine® 8 x 0.30 mm Needles: An Open, Randomized, Two-period Cross-over, Multi-centre, Phase IIIb Trial at 4 Centres

Sponsor: Novo Nordisk A/S

Conditions Delivery Systems Diabetes Diabetes Mellitus, Type 1

Interventions NovoFine® needle 6 mm NovoFine® needle 8 mm

Updated 8 times since 2017 Last updated: Aug 3, 2018 Started: Jan 20, 1998 Primary completion: Jul 27, 1998 Completion: Jul 27, 1998

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Delivery Systems and Diabetes, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 8 data snapshots since 1998. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2018 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Mar 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chieti, Italy